| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | JARID1A |
| Uniprot No | P29375 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 437-603aa |
| 活性数据 | EYALSGWNLNNMPVLEQSVLAHINVDISGMKVPWLYVGMCFSSFCWHIEDHWSYSINYLHWGEPKTWYGVPSHAAEQLEEVMRELAPELFESQPDLLHQLVTIMNPNVLMEHGVPVYRTNQCAGEFVVTFPRAYHSGFNQGYNFAEAVNFCTADWLPIGRQCVNHYR |
| 分子量 | 21.3 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | 0 |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇与重组人JARID1A蛋白相关的参考文献示例(内容基于公开研究主题概括，非真实文献)：
---
1. **文献名称**：Structural insights into the catalytic mechanism of JARID1A/KDM5A histone demethylase
**作者**：Christott T, et al.
**摘要**：本文解析了重组人JARID1A蛋白的晶体结构，揭示了其JmjC结构域催化组蛋白H3K4去甲基化的分子机制，并探讨了该酶在表观遗传调控中的构效关系。
---
2. **文献名称**：JARID1A regulates pluripotency in embryonic stem cells through histone modification
**作者**：Wang J, et al.
**摘要**：研究利用重组JARID1A蛋白进行体外实验，证明其通过动态调控H3K4me3水平维持胚胎干细胞多能性，并揭示了其与Oct4/Sox2复合物的功能互作。
---
3. **文献名称**：Development of JARID1A inhibitors for cancer therapy: Biochemical characterization and screening
**作者**：Højfeldt JW, et al.
**摘要**：作者通过重组表达纯化JARID1A蛋白，建立了高通量抑制剂筛选平台，筛选出小分子化合物并验证其对肿瘤细胞表观遗传重编程的干预作用。
---
*注：以上文献为模拟示例，实际引用请以真实发表论文为准。建议通过PubMed或Web of Science搜索关键词“recombinant JARID1A/KDM5A”获取最新研究。*
Recombinant human JARID1A protein, also known as lysine-specific demethylase 5A (KDM5A), is a key epigenetic regulator involved in modifying histone methylation marks. Belonging to the JARID1 subfamily, this enzyme specifically demethylates tri- and dimethylated histone H3 lysine 4 (H3K4me3/me2), modifications typically associated with active gene transcription. By dynamically erasing these epigenetic marks, JARID1A fine-tunes gene expression patterns critical for cellular differentiation, cell cycle progression, and stem cell maintenance. Structurally, it contains conserved domains including JmjC (catalytic domain), JmjN, PHD zinc fingers, and a BRIGHT domain, which mediate its enzymatic activity and chromatin-targeting functions.
Dysregulation of JARID1A has been implicated in cancer pathogenesis, where it may act as either an oncogene or tumor suppressor depending on cellular context. It contributes to drug resistance in malignancies by silencing tumor suppressor genes and modulating DNA damage responses. Additionally, JARID1A plays roles in developmental processes and neurological functions. Recombinant JARID1A protein, typically produced in Escherichia coli or mammalian expression systems, retains post-translational modifications and enzymatic activity when derived from eukaryotic hosts. This engineered protein serves as an essential tool for in vitro studies of chromatin remodeling mechanisms, high-throughput inhibitor screening for cancer therapy, and structural analysis of demethylase-substrate interactions. Its applications extend to investigating epigenetic crosstalk and developing targeted therapies for diseases linked to aberrant histone methylation.
×
